Gorter R W, van Wely M, Stoss M, Wollina U
Institute for Oncological and Immunological Research, Berlin, Germany.
Am J Ther. 1998 May;5(3):181-7. doi: 10.1097/00045391-199805000-00009.
Iscador, an aqueous extract of Viscum album L., has been widely used as an anti-cancer drug for several decades. Mistletoe lectins have the capacity to activate nonspecific defense mechanisms, and lectin-carbohydrate interactions may be involved in clinically applicable immunomodulation. During treatment with whole-plant mistletoe extract, an inflammatory reaction usually occurs at the site of the injection, early in therapy. These injection sites were examined histologically. Seven subjects received three subcutaneous injections of Iscador QuFrF or Iscador Qu Spezial (twice 0.1 mg and once 2.5 mg) during 9 days. In all subjects, examination of skin biopsies showed a normal epidermis. The dermal and subcutaneous regions contained a dense perivascular lymphocyte infiltrate and increased monocytes. We could not document any increase of plasma cells, eosinophils, mast cells, neutrophils, or granulocytes, as would be the case for a granulomatous infiltrate. In the blood, we observed a significant increase in neutrophils and monocytes 24 hours after administration of 2.5 mg of Iscador.
欧洲槲寄生提取物艾斯卡德（Iscador）作为一种抗癌药物已被广泛使用数十年。槲寄生凝集素能够激活非特异性防御机制，凝集素与碳水化合物的相互作用可能参与临床适用的免疫调节。在用全植物槲寄生提取物治疗期间，通常在治疗早期注射部位会发生炎症反应。对这些注射部位进行了组织学检查。7名受试者在9天内接受了3次皮下注射艾斯卡德QuFrF或艾斯卡德Qu Spezial（两次0.1毫克，一次2.5毫克）。在所有受试者中，皮肤活检检查显示表皮正常。真皮和皮下区域有密集的血管周围淋巴细胞浸润和单核细胞增多。我们未发现浆细胞、嗜酸性粒细胞、肥大细胞、中性粒细胞或粒细胞有任何增加，而肉芽肿浸润时会出现这种情况。在血液中，我们观察到在给予2.5毫克艾斯卡德后24小时，中性粒细胞和单核细胞显著增加。
